Worldwide Clinical and Real-World Exposure to Baricitinib

    November 2024 in “ SKIN The Journal of Cutaneous Medicine ”
    Ruth Ann Vleugels, Brittany G. Craiglow, Arash Mostaghimi, Elise A. Olsen, Angelina Sontag, Karen Denning, Najwa Somani, Maria Hordinsky
    From the encyclopedia
    Baricitinib →

    JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Image
    Studysummary This study found extensive real-world and clinical trial exposure to baricitinib across various disease states, ages, and racial populations, contributing data to its overall profile. Our plain-language summary of this paper — not a Tressless recommendation.
    Baricitinib (BARI), a JAK inhibitor, has been extensively used worldwide for conditions like rheumatoid arthritis, alopecia areata, atopic dermatitis, juvenile idiopathic arthritis, and COVID-19. An estimated 1,836,600 patients have been exposed to BARI in real-world settings, with 57% for COVID-19 treatment. Clinical trials have involved 14,660 subjects, including 866 patients under 18 years. The trials cover diverse racial backgrounds and age groups, from less than 1 month to over 65 years. While these exposures don't confirm efficacy or safety, they help establish BARI's overall profile and inform its performance across various populations.
    Discuss this study in the Community →